Sins and Risks in Underreporting Suspected Adverse Drug Reactions




Pharmacovigilance, Underreporting, Epistemic risk, Adverse drug reactions, Side effects


The underreporting of suspected adverse drug reactions remains a primary issue for contemporary post-market drug surveillance or pharmacovigilance. Pharmacovigilance pioneer W.H.W. Inman argued that “deadly sins” committed by clinicians are to blame for underreporting. Of these “sins,” ignorance and lethargy are the most obvious and impactful in causing underreporting. However, recent analyses show that diffidence, insecurity, and indifference additionally play a major role. I aim to augment our understanding of diffidence, insecurity, and indifference by arguing that these sins are underwritten by value judgments arising via epistemic risk. I contend that “evidence-based” medicine codifies these sins.


Anjum, Rani Lill, Samantha Copeland, and Elena Rocca. 2020. “Medical Scientists and Philosophers Worldwide Appeal to EBM to Expand the Notion of ‘Evidence’.” BMJ Evidence-Based Medicine 25, no. 1: 6–8.

Aronson, Jeffrey K. and Manfred Hauben. 2006. “Anecdotes That Provide Definite Evidence.” British Medical Journal 333, no. 7581: 1267–1269.

Ballentine, Carol. 1981. “Sulfanilamide Disaster.” FDA Consumer Magazine, June.

Betz, Gregor. 2013. “In Defense of the Value-Free Ideal.” European Journal for Philosophy of Science 3, no. 2: 207–220.

Biddle, Justin. 2007. “Lessons from the Vioxx Debacle: What the Privatization of Science Can Teach Us about Social Epistemology.” Social Epistemology 21, no. 1: 21–39.

———. 2013. “Institutionalizing Dissent: A Proposal for an Adversarial System of Pharmaceutical Research.” Kennedy Institute Ethics Journal 23, no. 4: 325–353.

———. 2016. “Inductive Risk, Epistemic Risk, and Overdiagnosis of Disease.” Perspectives on Science 24, no. 2: 192–205.

Biddle, Justin and Rebecca Kukla. 2017. “The Geography of Epistemic Risk.” In Exploring Inductive Risk: Case Studies of Values in Science, edited by Kevin C. Elliott and Ted Richards, 215–238. Oxford: Oxford University Press.

Bluhm, Robyn. 2005. “From Hierarchy to Network: A Richer View of Evidence for Evidence-Based Medicine.” Perspectives in Biology and Medicine 48, no. 4: 535–547.

Bluhm, Robyn and K. Borgerson. 2018. “An Epistemic Argument for Research-Practice Integration in Medicine.” Journal of Medicine and Philosophy 43, no. 4: 469–484.

Blunt, Christopher. 2015. “Hierarchies of Evidence in Evidence-Based Medicine.” PhD diss., London School of Economics and Political Science.

Brockmann, Rouen, Joanna Nixon, Bryan L. Love, and Ismaeel Yunusa. 2023. “Impacts of FDA Approval and Medicare Restriction on Antiamyloid Therapies for Alzheimer’s Disease: Patient Outcomes, Healthcare Costs, and Drug Development.” The Lancet Regional Health—Americas, article 100467.

Carpenter, Daniel. 2010. Reputation and Power: Organization Image and Pharmaceutical Regulation at the FDA. Princeton, NJ: Princeton University Press.

Cartwright, Nancy. 2007. “Are RCTs the Gold Standard?” Biosocieties 2, no. 1: 11–20.

Douglas, Heather. 2000. “Inductive Risk and Values in Science.” Philosophy of Science 67, no. 4: 559–579.

Due, Austin. 2022. “Are ‘Phase IV’ Trials Exploratory or Confirmatory Experiments?” Studies in History and Philosophy of Science 95, 126–133.

———. 2023. “What Are Side Effects?” European Journal for Philosophy of Science 13, article 16.

———. Forthcoming. “Is There a ‘Best’ Way for Patients to Participate in Pharmacovigilance?” Journal of Medicine and Philosophy.

Enkin, M.W. and A.R. Jadad. 1998. “Using Anecdotal Information in Evidence-Based Health Care: Heresy or Necessity?” Annals of Oncology 9, no. 9: 963–966.

García-Abeijon, Patricia, Caterina Costa, Margarita Taracido, Maria Teresa Herdeiro, Carla Torre, and Adolfo Figuerias. 2023. “Factors Associated with Underreporting of Adverse Drug Reactions by Health Care Professionals: A Systematic Review Update.” Drug Safety 46, no. 7: 625–636.

Goldenberg, Maya J. 2009. “Iconoclast or Creed? Objectivism, Pragmatism, and the Hierarchy of Evidence.” Perspectives in Biology and Medicine 52, no. 2: 168–187.

Guyatt, Gordon, Drummond Rennie, Maureen O. Meade, and Deborah J. Cooke, eds. 2015. Users’ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. 3rd ed. New York: McGraw Hill.

Hazell, Lorna and Saad A.W. Shakir. 2006. “Under-Reporting of Adverse Drug Reactions: A Systematic Review.” Drug Safety 29, no. 5: 385–396.

Hempel, Carl G. 1965. “Science and Human Values.” In Aspects of Scientific Explanation and Other Essays in the Philosophy of Science, 81–96. New York: The Free Press.

Herbst, A.L., H. Ulfelder, and D.C. Poskanzer. 1971. “Adenocarcinoma of the Vagina: Association of Maternal Stilbestrol Therapy with Tumor Appearance in Young Women.” New England Journal of Medicine 284, no. 15: 878–881.

Hicks, Daniel J. 2014. “A New Direction for Science and Values.” Synthese 191: 3271–3295.

Hohl, Corinne M., Serena S. Small, David Peddie, Katherin Badke, Chantelle Bailey, and Ellen Balka. 2018. “Why Clinicians Don’t Report Adverse Drug Events: Qualitative Study.” JMIR Public Health and Surveillance 4, no. 1, e21.

Holman, Bennett and Torsten Wilholt. 2022. “The New Demarcation Problem.” Studies in History and Philosophy of Science 91, 211–220.

Howick, Jeremy. 2011. “Exposing the Vanities—and a Qualified Defense—of Mechanistic Reasoning in Health Care Decision Making.” Philosophy of Science 78, no. 5: 926–940.

Inman, W.H.W. 1976. “Assessment of Drug Safety Problems.” In Epidemiological Issues in Reported Drug-Induced Illnesses, edited by M. Gent and I. Shigmatsu, 17–24. Honolulu: McMaster University Library Press.

Inman, W.H.W. and J.C.T. Weber. 1986. “The United Kingdom.” In Monitoring for Drug Safety, edited by W.H.W. Inman, 13–47. 2nd edition. Lancaster: MTP Press.

Kidd, Ian James. 2018. “Deep Epistemic Vices.” Journal of Philosophical Research 43: 43–67.

Kim, James H. and Anthony R. Scialli. 2011. “Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease.” Toxicological Sciences 122, no. 1: 1–6.

Light, Donald W., Joel Lexchin, and Jonathan J. Darrow. 2013. “Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs.” Journal of Law, Medicine, and Ethics 41, no. 3: 590–600.

Longino, Helen E. 1996. “Cognitive and Non-cognitive Values in Science: Rethinking the Dichotomy.” In Feminism, Science, and the Philosophy of Science, edited by Lynn Hankinson Nelson and Jack Nelson, 39–58. Dordrecht: Kluwer Academic Publishers.

Lopez-Gonzalez, Elena, Maria T. Herdeiro, and Adolfo Figuerias. 2009. “Determinants of Under-Reporting of Adverse Drug Reactions: A Systematic Review.” Drug Safety 32, no. 1: 19–31.

Merton, Robert K. 1938. “Science and the Social Order.” Philosophy of Science 5, no. 3: 321–337.

Mercuri, Mathew. Brian S. Baigrie, and Amiram Gafni. 2021. “Patient Participation in the Clinical Encounter and Clinical Practice Guidelines: The Case of Patients’ Participation in a GRADEd World.” Studies in History and Philosophy of Science 85: 192–199.

Moore, Nicholas. 2014. “An Historical Perspective of the Future of Pharmacovigilance.” In Mann’s Pharmacovigilance, edited by Elizabeth B. Andrews and Nicholas Moore, 807–817. 3rd edition. New York: Wiley & Sons.

Naina-Mohamed, Isa. 2014. “Pharmacovigilance and Reporting Adverse Drug Reactions.” Med & Health 9, no. 2: 92–102.

Onakpoya, Igho J., Carl J. Heneghan, and Jeffrey K. Aronson. 2016. “Post-marketing Withdrawal of 462 Medicinal Products because of Adverse Drug Reactions: A Systematic Review of the World Literature.” BMC Medicine 14, article 10.

Osimani, Barbara. 2014. “Hunting Side Effects and Explaining Them: Should We Reverse Evidence Hierarchies Upside Down?” Topoi 33: 295–312.

Palleria, Caterina, Christian Leporini, Serafina Chimirri, Giuseppina Marrazzo, Sabrina Sacchetta, Lucrezia Bruno, Rosaria M. Lista, et al. 2013. “Limitations and Obstacles of the Spontaneous Adverse Drugs Reactions Reporting: Two ‘Challenging’ Case Reports.” Journal of Pharmacology & Pharmacotherapeutics 4, suppl. 1: S66–S72.

Rudner, Richard. 1953. “The Scientist Qua Scientist Makes Value Judgements.” Philosophy of Science 20, no. 1: 1–6.

SAHPRA (South African Health Products Regulatory Authority). 2022. Post-marketing Reporting of Adverse Drug Reactions to Human Medicines in South Africa.

Steel, Daniel. 2017. “Qualified Epistemic Priority: Comparing Two Approaches to Values in Science.” In Current Controversies in Values and Science, edited by Kevin C. Elliott and Daniel Steel, 49–63. New York: Routledge.

Stegenga, Jacob. 2011. “Is Meta-analysis the Platinum Standard of Evidence?” Studies in History and Philosophy of Biology and Biomedical Sciences 42, no. 4: 497–507.

———. 2016. “Hollow Hunt for Harms.” Perspectives on Science 24, no. 5: 481–504.

Upshur, Ross E.G., Elizabeth G. VanDenKerkhof, and Vivek Goel. 2001. “An Inclusive Model of Evidence in Health Care.” Journal of Evaluation in Clinical Practice 7, no. 2: 91–96.

Van Zee, Art. 2009. “The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy.” American Journal of Public Health 99, no. 2: 221–227.

Viljoen, M. and G.I. Muntingh. 2022. “Adverse Drug Reactions: To Report, or Not to Report?” South African General Practitioner 3, no. 2.

Wadman, Meredith. 2005. “Journal Grows Suspicious of Vioxx Data.” Nature 438, no. 770, article 899.

Wilholt, Torsten. 2009. “Bias and Values in Scientific Research.” Studies in History and Philosophy of Science 40, no. 1: 92–101.

Worrall, John. 2008. “Evidence and Ethics in Medicine.” Perspectives in Biology and Medicine 51, no. 3: 418–431.

Wysowski, Diane K. and Lynette Swartz. 2005. “Adverse Drug Event Surveillance and Drug Withdrawals in the United States, 1969–2002: The Importance of Reporting Suspected Reactions.” Archives of Internal Medicine 165, no. 12: 1363–1369.




How to Cite

Due, A. (2024). Sins and Risks in Underreporting Suspected Adverse Drug Reactions . Philosophy of Medicine, 5(1).



Original Research Articles (clinical research, evidence-based medicine)